Tango Therapeutics, Inc. (TNGX)
$
12.2
-0.15 (-1.23%)
Key metrics
Financial statements
Free cash flow per share
-1.3226
Market cap
1.4 Billion
Price to sales ratio
21.2625
Debt to equity
0.2172
Current ratio
8.8798
Income quality
1.4507
Average inventory
0
ROE
-0.6080
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tango Therapeutics, Inc. is engaged in the discovery and development of innovative drugs aimed at treating cancer. The company's lead candidate, TNG908, is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 and is being explored as a treatment for cancers characterized by methylthioadenosine phosphorylase deletions. Additionally, Tango Therapeutics is developing Ubiquitin-specific protease 1, which targets patients with BRCA1 or BRCA2-mutant cancers, and is also focused on Target 3 for STK11-mutant cancers. The net total of other income and expenses is $15,501,000.00 reflecting non-core financial activities. The company reported an income before tax of -$130,094,000.00 showcasing its pre-tax profitability, while the weighted average number of shares outstanding is 109,226,731.00 highlighting the company's shareholder base. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations, and the EBITDA ratio is -3.40 indicating the company's operational efficiency. Tango Therapeutics has formed a strategic partnership with Gilead Sciences, Inc. to advance the discovery, development, and commercialization of a diverse pipeline of therapies aimed at cancer patients. Founded in 2017, the company is headquartered in Cambridge, Massachusetts. In the current financial landscape, the stock is affordable at $7.60 making it an attractive option for budget-conscious investors. With a high average trading volume of 2,833,108.00 the stock indicates strong liquidity, which is essential for potential investors. The company, with a market capitalization of $1,347,694,679.00 is classified as a small-cap player in the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and being part of the Healthcare sector emphasizes its role in driving innovation and growth within the field.
Is Tango Therapeutics, Inc. (TNGX) a good investment?
Investing in Tango Therapeutics, Inc. (TNGX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Tango Therapeutics, Inc. (TNGX)'s stock forecast?
Analysts predict Tango Therapeutics, Inc. stock to fluctuate between $1.03 (low) and $13.48 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tango Therapeutics, Inc.'s market capitalization?
As of 2026-02-20, Tango Therapeutics, Inc.'s market cap is $1,347,694,679, based on 110,466,777 outstanding shares.
How does Tango Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Tango Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tango Therapeutics, Inc. (TNGX) stock?
To buy Tango Therapeutics, Inc. (TNGX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TNGX. Place an order (Market, Limit, etc.).
What is the best time to invest in Tango Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Tango Therapeutics, Inc. perform in the last earnings report?
Revenue: $42,069,000 | EPS: -$1.19 | Growth: 10.19%.
Where can I find Tango Therapeutics, Inc.'s investor relations reports?
Visit https://www.tangotx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tango Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Tango Therapeutics, Inc. stock?
All-time high: $18.84 (2021-09-17) | All-time low: $1.03 (2025-05-08).
What are the key trends affecting Tango Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
zacks.com
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
seekingalpha.com
Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications.
zacks.com
Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago.
fool.com
Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025.
zacks.com
Tango Therapeutics (TNGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
seekingalpha.com
Tango Therapeutics, Inc. (NASDAQ:TNGX ) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers October 23, 2025 8:30 AM EDT Company Participants Elizabeth Hickin - VP of IR & Corporate Communications Barbara Weber - President, CEO & Director Adam Crystal - President of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good day.
benzinga.com
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.
zacks.com
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
See all news
